Genvec (GNVC) Inactive USPTO patentsUtility grant

Utility

Simian (gorilla) adenovirus or adenoviral vectors and methods of use

14 Jun 22

The invention provides an adenovirus or adenoviral vector characterized by comprising one or more particular nucleic acid sequences or one or more particular amino acid sequences, or portions thereof, pertaining to, for example, an adenoviral pIX protein, DNA polymerase protein, penton protein, hexon protein, and/or fiber protein.

Douglas E. Brough, Jason G. D. Gall, Duncan McVey

Filed: 25 Aug 20

Utility

Adenoviral vector encoding human atonal homolog-1 (HATH1)

22 Mar 22

The invention is directed to a replication-deficient adenoviral vector comprising a nucleic acid sequence encoding a human atonal homolog-1 (Hath1) protein operably linked to a human glial fibrillary acidic protein (GFAP) promoter.

Douglas E. Brough, Damodar R. Ettyreddy

Filed: 23 Mar 18

Utility

moctx8rw0r0l0178uauoqlw64zuft 3tsi5arnbgueszgcvh

26 Oct 21

The invention provides adenoviral vectors and compositions for the highly efficient transduction of T cells.

Sebastien M. Maloveste, Damodar Ettyreddy, Douglas E. Brough

Filed: 29 Sep 17

Utility

uumra1ywryvd94aoz9o5m3e

15 Jun 21

The invention provides an adenovirus or adenoviral vector characterized by comprising one or more particular nucleic acid sequences or one or more particular amino acid sequences, or portions thereof, pertaining to, for example, an adenoviral pIX protein, DNA polymerase protein, penton protein, hexone protein, and/or fiber protein.

Jason G. D. Gall, Duncan McVey, Douglas E. Brough

Filed: 22 Feb 19

Utility

4sezomoq06v2s5 ykr9std

16 Mar 21

The invention provides a replication-deficient serotype 28 adenoviral vector characterized by comprising a portion of a serotype 45 adenoviral hexon protein and/or a portion of a serotype 45 fiber protein in place of the endogenous serotype 28 hexon and/or fiber protein.

Lisa Wei, Douglas E. Brough, C. Richter King

Filed: 11 Sep 17

Utility

j6nww1ehp0vuzjyha0mco0p9lkmup4urkn49bjl9wz6qymle4gy7xrdspn

5 Oct 20

The invention provides an adenovirus or adenoviral vector characterized by comprising one or more particular nucleic acid sequences or one or more particular amino acid sequences, or portions thereof, pertaining to, for example, an adenoviral pIX protein, DNA polymerase protein, penton protein, hexon protein, and/or fiber protein.

Duncan McVey, Douglas E. Brough, Jason G. D. Gall

Filed: 12 Mar 19

Utility

d289gs5f00todirajioaci6re4v

28 Sep 20

The invention provides an adenovirus or adenoviral vector characterized by comprising one or more particular nucleic acid sequences or one or more particular amino acid sequences, or portions thereof, pertaining to, for example, an adenoviral pIX protein, DNA polymerase protein, penton protein, hexon protein, and/or fiber protein.

Douglas E. Brough, Jason G. D. Gall, Duncan McVey

Filed: 23 Jul 18

Utility

d69uhovtq3vv6xab169kvsjk0hj671vugr66k4a9iw183

21 Sep 20

The invention is directed to a composition comprising one or more polypeptides or one or more nucleic acid sequences that can induce a protective immune response against Plasmodium species that infect humans.

Ping Chen, Duncan McVey, Douglas E. Brough, Joseph Bruder

Filed: 23 Apr 19

Utility

2wqwma8tqjx8 yvqy43te8yqr6dkanoxw481wisj

4 May 20

The invention provides a method of propagating an adenoviral vector.

Jason G. D. Gall, Douglas E. Brough, C. Richter King

Filed: 6 Sep 17

Utility

an90wjzyr05876z8i7s78teuugrch3o9e3gjzdl6760ogjylllp

2 Dec 19

The present invention encompasses FMDV vaccines or compositions.

Justin Widener, Leszlie Woodyard, Leonardo Siger, Douglas Brough, Damodar Ettyreddy, Jason Gall, Duncan McVey, Tom Burrage, Lauri Motes-Kreimeyer, Marc Fiorucci

Filed: 16 Jan 19